| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2019: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2018: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2017: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2016: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we clarified a novel mechanism of MMP13 expression control by mechanical stimulation. In addition, it was clarified that the signaling pathway of this mechanical stimulation employs PLGC1 as a crosstalk point with the cytokine signal that causes cartilage degeneration. In addition to clarifying the new regulatory mechanism of MMP13, we found many small molecules that suppress the expression of MMP13 by cytokine and mechanical stimulation in drug screening. It can be said that the discovery of a low-molecular compound that suppresses signaling pathways of cytokines and multiple MMP13 has brought us closer to the realization of a disease-modifying osteoarthritis therapeutic drug.
|
